Digital twins market projection

A market forecast released April 22 says healthcare digital twins could jump from a niche software category to a $101.19 billion business by 2031. (finance.yahoo.com) MarketsandMarkets put the market at about $7.47 billion in 2026 and projected a 68.4% compound annual growth rate through 2031 in a report published in May 2025 and promoted this week. (marketsandmarkets.com) A digital twin is a software model that mirrors a real person, device, or process and updates as new data comes in. The idea came out of engineering, where a virtual copy of a machine is used to test changes before touching the real one. (nature.com) In healthcare, that can mean a model of a patient’s heart, lungs, tumor, hospital workflow, or drug-production line. Reviews in *npj Digital Medicine* and *Frontiers in Digital Health* say the main uses are prediction, treatment planning, training, and operations. (nature.com) (pmc.ncbi.nlm.nih.gov) Regulators are paying attention because the same software stack behind digital twins sits inside a broader wave of digital health tools. The Food and Drug Administration says digital health technologies include software, sensors, connectivity, and computing platforms used for healthcare and related uses. (fda.gov) Public agencies are also funding the field. In late 2024, the National Science Foundation, National Institutes of Health, and Food and Drug Administration said they had awarded more than $6 million across seven projects to study digital twins for healthcare and biomedical research. (nsf.gov) The commercial pitch is broad: personalized medicine, drug discovery, medical education, and workflow optimization are the four application buckets highlighted in the MarketsandMarkets report. Software is the core product category in that forecast, with services layered on top. (marketsandmarkets.com) But the most tightly regulated uses are moving more selectively than the revenue curve suggests. A 2025 pharmaceutical review described digital twins in drug development and continuous manufacturing as promising for monitoring and prediction, while a 2024 manufacturing paper said adoption still turns on validation, regulatory expectations, and operator decision support. (pmc.ncbi.nlm.nih.gov) (mdpi.com) European medicines officials are framing patient-specific digital twins as tools for prevention, diagnosis, and treatment selection, but still as part of an “in silico” spectrum rather than a finished clinical standard. That leaves room for pilots, modeling work, and targeted deployment before routine use at scale. (ema.europa.eu) So the headline number points to investor and vendor appetite more than universal rollout by hospitals or drug plants. The next few years will show whether the fastest growth comes from software sold around healthcare, or from digital twins trusted inside regulated care and manufacturing decisions. (marketsandmarkets.com) (fda.gov)